Company Overview and News

 
Hester Biosciences Limited - Record Date

2018-08-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HESTERBIO 524669

 
Hester Biosciences Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HESTERBIO 524669

 
Hester Biosciences Limited - Shareholders meeting

2018-08-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HESTERBIO 524669

 
Hester Biosciences Limited - Shareholders meeting

2018-08-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HESTERBIO 524669

 
Hester Biosciences Limited - Dividend

2018-08-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HESTERBIO 524669

 
Hester Biosciences Limited - Dividend

2018-08-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HESTERBIO 524669

 
Hester Biosciences Limited - Press Release

2018-08-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HESTERBIO 524669

 
Hester Biosciences Limited - Financial Result Updates

2018-08-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HESTERBIO 524669

 
Hester Biosciences Limited - Updates

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HESTERBIO 524669

 
Hester Biosciences Limited - Book Closure

2018-07-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HESTERBIO 524669

 
Trump's trade war is already failing on signature campaign promise

2018-06-01 cnbc
President Trump has doubled down on his retrograde protectionist policies by announcing new metals tariffs on the European Union, Mexico, and Canada. Aside from causing unnecessary conflict with some of our allies, these tariffs are doomed to fail.
HESTERBIO 524669

 
Hester Biosciences Limited - Updates

2018-05-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HESTERBIO 524669

 
Hester Biosciences Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HESTERBIO 524669

30
Market Live: Sensex trades lower, Nifty hovers around 10800; midcaps, auto stocks fall

2018-05-14 moneycontrol
Some weakness is now seen on the D-Street as it gets ready for the outcome of Karnataka assembly polls on Tuesday. The Sensex is down over 50 points, while the Nifty is trading around 10,780-levels. Midcaps have further extended their fall, pharma and PSU banks have trimmed some of the gains. Auto stocks too continued to trade lower. Dr Reddy’s Labs, NTPC, and SBI were the top gainers, while Tata Motors, M&M, Titan and Indiabulls Housing were the top losers.
MAHLIFE 500325 500820 RELIANCE 539336 HCTHY HINDUNILVR 532218 BHRQY ASIANPAINT 533278 532313 MGEVF SOUTHBANK 500470 532121 532483 ALLCARGO RIGD 500696 532281 500356 500570 BHARTIARTL TATAMOTORS CLNDY RLNIY 524669 IBN 532749 RAMANEWS CNRYY 532454 HESTERBIO GUJGAS ICICIBANK TTST TATASTEEL TATLY 532174 HCLTECH CANBK DENABANK COALINDIA TTM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...